Introducing Violet™ Iodine, New Once-Daily, Non-Prescription Pill For Relief Of Premenstrual Breast Discomfort*
Formulated to Help Alleviate Symptoms Associated with Fibrocystic Breast Condition for the Estimated 50 Percent of Women Aged 15 to 49 Who Suffer from Monthly Breast Discomfort
Dec 9, 2014
“Fibrocystic breast condition is the generally accepted term to describe a common, benign condition that is associated with varying levels of monthly breast discomfort, including breast tenderness, aches, swelling, and heaviness,” said Dr. Lisa Masterson, OBGYN. “FBC affects an estimated 50 percent of women between the ages of 15-49,1or over 35 million women in America, which is why I am thrilled there is now an option for my patients and the many women living with this condition to manage their discomfort.”
Fibrocystic breast condition is thought to be caused by hormonal imbalances, which can cause breast tissue growth to exceed its natural cell turnover. Breast tissue builds up month after month with each menstrual cycle, resulting in swollen, achy and tender breasts.
Daily use of Violet iodine can help normalize these imbalances and address the underlying causes of fibrocystic breast condition, thereby alleviating symptoms that vary in severity from general soreness to clinically diagnosed FBC.* One clinical study showed that women taking a daily dose of either 3 or 6 mg of iodine showed a decrease in monthly breast discomfort relative to women taking a daily dose of either a placebo or 1.5 mg of iodine.1*
“What is unique about Violet iodine is its non-hormonal formula of patented molecular iodine, which aims to target the breast tissue with limited introduction in the thyroid,”* said Dr. Lee P. Shulman, Professor and Head of the Section of Reproductive Genetics in the Department of Obstetrics and Gynecology at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois. “Adding Violet iodine to a woman’s daily regimen can help safely relieve the most common forms of breast pain and discomfort, including aches and swelling, while also maintaining healthy breast tissue.”*
When taken daily, Violet iodine can begin to provide relief of symptoms after several months or approximately two menstrual cycles, though some women see relief much sooner.* Beyond FBC, Violet iodine can support women through breast tissue changes over the course of their lives by maintaining healthy cell growth – from onset of menstruation to menopause.* Daily consumption of iodine is typically safe for most people.
“Discomfort from monthly breast pain associated with fibrocystic breast condition can impact a woman’s lifestyle, from restricting the types of clothes she wears and limiting her ability to exercise regularly to preventing her from hugging loved ones,” said Anja Krammer, President, BioPharmX. “We’re excited to finally bring to market a product in Violet iodine that will help the millions of women whose breast discomfort has interfered with their daily lives for far too long.”*
Violet iodine is now available for sale online without a prescription in 30 and 60 count packages and can be found in the feminine care aisle of major retailers beginning 2015.
About Violet™ Iodine
Violet iodine is a daily iodine supplement for the relief of the most common symptoms of cyclic mastalgia and fibrocystic breast condition (FBC), including monthly swelling, tenderness, aches and heaviness. Violet iodine is available in 30 and 60 count packages at Walgreen Co.’s (NYSE: WAG) (NASDAQ: WAG) drugstore.com™ web store. To learn more about Violet iodine, visit www.VioletDaily.com.
About Fibrocystic Breast Condition (FBC)
Fibrocystic breast condition (FBC) is the generally accepted term to describe common, benign breast discomfort caused by the influx of hormones during the menstrual cycle. FBC, which affects an estimated 50 percent of women ages 15 to 49,1 can cause monthly breast tenderness, aches, swelling, and heaviness. In women with FBC, the hormones estrogen and prolactin cause breast cells to build up month over month with each menstrual cycle, causing swollen breast tissue that can develop into lumps and masses. While a benign condition, FBC can impact many aspects of a woman’s life, including intimacy, clothing selection and exercise.
About BioPharmX Corporation
BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter (“OTC”), and supplement applications in the fast-growing health and wellness markets, including women’s health, dermatology, and otolaryngology (ears, nose & throat). To learn more about BioPharmX, visit www.BioPharmX.com.
Statements in this news release relating to the business of BioPharmX, which are not historical facts, are “forward-looking statements.” These forward-looking statements may be identified by words such as “expect,” “anticipate,” “believe,” or similar expressions that are intended to identify such forward-looking statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company’s filings with the Securities and Exchange Commission (SEC). Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Violet is a trademark of BioPharmX Inc.
*These statements have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
BioPharmX Media Relations
Cohn & Wolfe, on behalf of BioPharmX
1 JH Kessler, “The Effect of Supraphysiologic Levels of Iodine on Patients with Cyclic Mastalgia” The Breast Journal, 2004; 10(4) 328–336. Note: The Kessler study did not include selenium and included sodium iodide and sodium iodate instead of potassium iodide and potassium iodate.